Aclaris Therapeutics, Inc.
No SEC Form 4 filings for $ACRS in the last 30 days.
See all $ACRS insider activity →Aclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 27, 2026, Aclaris Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representativ
Aclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma - Results Demonstrated Breadth and Rapidity of Response to ATI-052 in Heterogeneous Patient P
Aclaris Therapeutics reported positive Phase 1b data for ATI-052 in treating atopic dermatitis and asthma, with favorable safety profile. The company plans to prioritize a Phase 2b trial for eosinophilic esophagitis.
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning ACRS (Aclaris Therapeutics, Inc.). Coverage has skewed bearish: 3 bullish, 0 neutral, and 6 bearish.
Recent ACRS coverage spans financial news, corporate actions and earnings.
The secondary offering will increase share supply and may dilute existing shareholders.
The data show rapid, durable efficacy and a favorable safety profile, suggesting strong commercial potential and likely near‑term share price upside.
Positive early‑stage trial results typically lift biotech stocks as investors anticipate further value creation.
Analyst reiteration may sustain current price but overvaluation concerns could limit upside.
The filing discloses an updated ATM sales program framework, which can increase dilution risk and affect near-term supply/demand dynamics.
AlphAI scores every news story that mentions ACRS with an AI model for sentiment and relevance, and aggregates insider trades from Aclaris Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Aclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 27, 2026, Aclaris Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representativ
2 min readAclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma - Results Demonstrated Breadth and Rapidity of Response to ATI-052 in Heterogeneous Patient P
2 min readAclaris Therapeutics reported positive Phase 1b data for ATI-052 in treating atopic dermatitis and asthma, with favorable safety profile. The company plans to prioritize a Phase 2b trial for eosinophilic esophagitis.
1 min readCantor Fitzgerald reiterated an Overweight rating on Aclaris Therapeutics (ACRS), citing its promising pipeline. The stock is down 14% this week but up 140% over a year. Analysts highlight potential in its atopic dermatitis and asthma treatments, with key data expected in 2026. Other firms also issued positive ratings and price targets.
2 min readAclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 6, 2026, Aclaris Therapeutics, Inc. (the “Company”) entered into a Second Amended and Restated Sales Agreement (the “Amended ATM Agreement”) with Leerink Partners LLC (“Leerink”) and Cantor Fitzgerald & Co. (“Cantor”
3 min readAclaris Therapeutics, Inc. (ACRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing -
6 min readA dpa-AFX report says Bioventus (BVS), Trevi Therapeutics (TVTX), Odonate Therapeutics (ODTX) and Corcept? (CRL) hit 52-week highs on Aug. 5, 2026, after positive Q2 results. It also references Aclaris Therapeutics (ACRS) in the same context.
4 min readBiotech stocks hit 52-week highs on July 20, 2026, attributed to upcoming clinical catalysts. Xencor (XNCR) reached $20.26, up 7%, with Phase 2b XENITH-UC interim results expected by year-end 2026. Hemab (COAG) hit $52.15 after positive Phase 2 Sutacimig data. Monopar (MNPR) hit $115 on Phase 3 ALXN1840 Wilson disease results. SOPHiA (SOPH) rose above $6.50; Q1 revenue was $21.7M and 2026 guidance is $92M to $94M.
4 min readAclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biotech company, has received a consensus 'Moderate Buy' recommendation from analysts, with an average 12-month price target of $9.80 per share. This rating reflects potential in the company's pipeline for dermatological conditions, despite varying analyst recommendations from 'sell' to 'strong buy'. The stock opened at $3.75 on Wednesday, April 8, 2026, with a 52-week range of $1.05 to $4.89.
2 min readAclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in the Leerink Partners 2026 Global Healthcare Conference. Dr. Neal Walker, CEO, and other senior leaders will host a fireside chat on March 10, 2026, at 1:40 PM EDT. A live webcast will be available on the company's website.
3 min read
